Bank of New York Mellon
CGON icon

Bank of New York Mellon’s CG Oncology CGON Stock Holding History

Bank of New York Mellon’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
233,419
+66,389
+40% +$4.34M ﹤0.01% 1743
2026
Q1 		$11.3M Buy
167,030
+11,874
+8% +$673K ﹤0.01% 1872
2025
Q4 		$6.44M Sell
155,156
-4,436
-3% -$184K ﹤0.01% 2179
2025
Q3 		$6.43M Buy
159,592
+12,929
+9% +$376K ﹤0.01% 2178
2025
Q2 		$3.81M Sell
146,663
-897
-0.6% -$21.6K ﹤0.01% 2419
2025
Q1 		$3.61M Buy
147,560
+11,993
+9% +$337K ﹤0.01% 2389
2024
Q4 		$3.89M Sell
135,567
-9,359
-6% -$320K ﹤0.01% 2420
2024
Q3 		$5.47M Buy
144,926
+55,582
+62% +$1.95M ﹤0.01% 2252
2024
Q2 		$2.82M Buy
89,344
+24,801
+38% +$860K ﹤0.01% 2606
2024
Q1 		$2.83M Buy
+64,543
New +$2.64M ﹤0.01% 2585

Other funds holding CGON

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon's CGON Position: Q2 2026 in Review

Bank of New York Mellon increased its CG Oncology (CGON) stake by 40% in Q2 2026, buying an estimated $4.34M and bringing the position to 233,419 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Bank of New York Mellon first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 110 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Bank of New York Mellon held 233,419 shares of CG Oncology worth $16.6M as of Q2 2026.
  • Bank of New York Mellon bought 66,389 CG Oncology shares in Q2 2026, an estimated $4.34M.
  • CG Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1743 holding.
  • Bank of New York Mellon first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 110 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.